P

Prothena Corp

D
PRTA
USD
-0.86
(-4.6892%)
Market Closed
18,387.00
Volume
-2.245
EPS
-
Div Yield
-18.595745
P/E
940,080,430.60
Market Cap
Today
-4.6892%
1 Week
2.763%
1 Month
5.301%
6 Months
-25.838%
12 Months
-51.925%
Year To Date
-51.925%
All Time
-70.876%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
S
SGEN
(%)
USD
MRNA
MRNA
-1.49
(-2.8776%)
USD
I
IMUX
-0.02
(-1.6667%)
USD
BMY
BMY
-0.57
(-1.0313%)
USD
GILD
GILD
6.23
(6.7946%)
USD
REGN
REGN
8.505
(1.0417%)
USD
ALNY
ALNY
-0.795
(-0.2913%)
USD
VRTX
VRTX
2.47
(0.494%)
USD
B
BLUE
-0.0615
(-14.0764%)
USD
I
INCY
1.47
(1.8173%)
USD

Title:
Prothena Corp

Sector:
Healthcare
Industry:
Biotechnology
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
Do you need help or have a question?
Contact Us